Parkinson's Movement
12,720 members11,302 posts

new treatment

New treatment option for Parkinson’s disease launched in the UK

The Pharmaceutical Journal18 OCT 2016

Drug company BIAL Pharm UK has launched opicapone (Ongentys), a new drug to improve mobility in some adult patients with Parkinson’s disease, for use in the UK.

Opicapone works by restoring the levels of dopamine in the brain, which controls movement and coordination; it also enhances the effects of levodopa, which helps with movement.

As such, the drug is recommended for use as an add-on to levodopa/DOPA decarboxylase inhibitors in patients with Parkinson’s disease who experience fluctuations in the control of their condition and their ability to move.

It was granted a marketing authorisation by the European Commission in June 2016, following a positive assessment in April 2016 by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).

The assessment was based on two trials, the results of which showed that opicapone was more effective than placebo and at least as effective as the comparator entacapone in reducing “off periods” — where a patient has difficult moving — in patients with Parkinson’s disease taking levodopa combination medicines.

BIAL says it anticipates additional EU launches of the product in the next 12 months.

17 Replies
oldestnewest

I think Xadago is better than this as it is neuroprotective as well as extending on time. It is interesting though.

Reply

I am from India. Can someone help me to get Xadago ? thanks

Reply

Anbu there is no drug called that. I guess it's Azilect which is very expensive I believe.

Reply

Incorrect. xadago is a new high performance pd drug

1 like
Reply

My apologies rhenry, yes I see there is a med called xadago. Thanks for that.

From what I have read it is used like opicopone for motor fluctuations and is an add on to levadopa, but I can't see anything about neuro protection?

Reply

It is highly neuroprotective. Please watch this video. vimeo.com/116166647

Reply

Looks very promising but there is no claim to be highly neroprotective, They are much more cautious saying it may be - here is hoping.

Reply

Dear Hikoi,

Xadago is a new drug introduced in the Europe. It is not available in the Americas since FDA has not approved it. Are you a Japanese by any chance? Name sounds like that. Regards.

1 like
Reply
1 like
Reply

I am not able to get it

1 like
Reply

I have always been able to get meds from Goldpharma.

Reply

Hi, were you able to import xadago ? I am from india too and looking at getting this medicine for my father. please mail me at tonmoy.it@gmail.com if you have anything to share.

Reply

Why is this not available in the US?

Reply

Thanks a lot rhenry. We have a problem in importing into India.

Reply

I am sure goldpharma ships to India. It says so in their shipping descriptions. you will be fine.

1 like
Reply

Thanks again. Will talk to them. Regards

Reply

Opicapone is a type of drug called a COMT inhibitor and similar to others already in use.

COMT inhibitors reduce Parkinson's symptoms by blocking an enzyme that breaks down levodopa, prolonging its effect.

However unlike other COMT inhibitors, opicapone only needs to be taken once a day and so could reduce the overall number of tablets required.

parkinsons.org.uk/news/18-o...

Entacapone is also a COMT inhibitor but needs to be taken multiple times a day.

1 like
Reply

You may also like...